This meta-analysis incorporated data from four pivotal clinical trials (Natalee, monarchE, PENELOPE-B, and PALLAS) that assessed the efficacy of CDK4/6 inhibitors in the adjuvant treatment of HR+/HER2− early breast cancer. Here, CDK4 is linked to breast carcinoma.